Market closedNon-fractional
ArriVent BioPharma/AVBP
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX
About ArriVent BioPharma
ArriVent BioPharma Inc is a clinical stage biopharmaceutical company dedicated to the identification, development and commercialization of differentiated medicines to address the unmet medical needs of patients with cancers. It seeks to utilize team's deep drug development experience to maximize the potential of lead development candidate, furmonertinib, and advance a pipeline of novel therapeutics, such as next-generation antibody drug conjugates, through approval and commercialization in patients suffering from cancer, with an initial focus on solid tumors.
Ticker
AVBP
Sector
Healthcare
Trading on
NASDAQ
Industry
Biotechnology
Headquarters
Newtown Square, United States
Employees
40
Website
www.arrivent.com
AVBP Metrics
BasicAdvanced
$708M
Market cap
-
P/E ratio
-$9.23
EPS
-
Beta
-
Dividend rate
Price and volume
Market cap
$708M
Financial strength
Current ratio
32.823
Quick ratio
31.9
Long term debt to equity
0.043
Total debt to equity
0.09
Management effectiveness
Return on equity (TTM)
-30.30%
Valuation
Price to book
2.26
Price to tangible book (TTM)
2.26
Price to free cash flow (TTM)
-2.966
Growth
Earnings per share change (TTM)
-71.69%
What the Analysts think about AVBP
Analyst Ratings
Majority rating from 5 analysts.
AVBP Financial Performance
Income StatementBalance sheetCash Flow
Income Statement
Revenues and expenses
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$0
NaN%
Net income
-$17M
-17.54%
Profit margin
0.00%
NaN%
AVBP Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q1 24
Q2 24
Actual
-$0.70
-
Expected
-$1.10
-$0.66
Surprise
-36.20%
-
AVBP News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market closedNon-fractional
Upcoming events
No upcoming events
FAQs
What’s the current market cap for ArriVent BioPharma stock?
ArriVent BioPharma (AVBP) has a market cap of $708M as of July 27, 2024.
What is the P/E ratio for ArriVent BioPharma stock?
The price to earnings (P/E) ratio for ArriVent BioPharma (AVBP) stock is 0 as of July 27, 2024.
Does ArriVent BioPharma stock pay dividends?
No, ArriVent BioPharma (AVBP) stock does not pay dividends to its shareholders as of July 27, 2024.
When is the next ArriVent BioPharma dividend payment date?
ArriVent BioPharma (AVBP) stock does not pay dividends to its shareholders.
What is the beta indicator for ArriVent BioPharma?
ArriVent BioPharma (AVBP) does not currently have a Beta indicator.
Buy or sell ArriVent BioPharma stock
Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.